Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

June 29, 2020

Study Completion Date

June 29, 2020

Conditions
Prostate Cancer
Interventions
DRUG

Docetaxel

60 mg/m² q 3 weeks for 3 cycle at the start of treatment followed by weekly Docetaxel at 20 mg/m² per week beginning at week one of radiation therapy and continuing for seven weeks.

DRUG

Androgen Hormonal Suppression and Radiation

Total Androgen Ablation and external beam radiation therapy

DRUG

Androgen Suppression Therapy and Radiation Therapy

Total Androgen Ablation and External Beam Radiation Therapy

Trial Locations (1)

02115

Dana-Farber Cancer Institute and (Sanofi-Aventis Consortium), Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER